Eli Lilly and Company (NYSE:LLY) Price Target Lowered to $1,163.00 at Guggenheim

Eli Lilly and Company (NYSE:LLY) had its price target reduced by equities researchers at Guggenheim from $1,168.00 to $1,163.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 30.24% from the company’s current price.

Several other analysts also recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research note on Tuesday, February 10th. Finally, Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,221.26.

Eli Lilly and Company Price Performance

Shares of LLY opened at $892.99 on Monday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a market capitalization of $843.71 billion, a price-to-earnings ratio of 38.87, a price-to-earnings-growth ratio of 1.02 and a beta of 0.40. The firm has a 50-day simple moving average of $1,007.25 and a 200-day simple moving average of $964.88. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the prior year, the business earned $5.32 EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently bought and sold shares of LLY. Exencial Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC bought a new position in Eli Lilly and Company during the third quarter valued at about $487,000. Central Pacific Bank Trust Division lifted its holdings in Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after acquiring an additional 1,843 shares during the last quarter. Cidel Asset Management Inc. lifted its position in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Big AI R&D pact — Lilly expanded its collaboration with Insilico Medicine in a deal worth up to $2.75 billion to accelerate AI-driven drug discovery; the agreement gives Lilly exclusive rights to programs and includes upfront and milestone payments, reinforcing growth optionality and R&D scale. Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
• Positive Sentiment: Clinical readout boosts pipeline optionality — Late?breaking Phase 3b TOGETHER?PsA data showed Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy vs Taltz alone in psoriatic arthritis patients with obesity, supporting cross?product synergies and potential label/market expansion. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz plus Zepbound delivered superior efficacy
• Positive Sentiment: Analyst support — Jefferies reiterated a Buy on LLY with a $1,300 price target, citing strong GLP?1 prescription data and continued franchise momentum, which can underpin investor confidence despite recent volatility. Jefferies Remains a Buy on Eli Lilly
• Neutral Sentiment: Macro/market mentions — Lilly is featured among broader market movers and media commentary (Jim Cramer, coverage pieces) that may amplify flows but are not new company?specific catalysts. These Stocks Are Today’s Movers
• Negative Sentiment: UK pricing / investment threat — Reports say Lilly is seeking regular NHS price increases and changes to rebate rules as conditions to restart UK investment; this kind of public negotiation raises political and reimbursement risk that can pressure valuation and access in a major market. Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment
• Negative Sentiment: Valuation and short?term pullback concerns — Commentary and screeners flag an ongoing price pullback and questions about whether the stock is priced for perfection, which can trigger further profit?taking after a multiyear run. Is It Time To Reassess Eli Lilly After The Recent Share Price Pullback?
• Negative Sentiment: Legal/operational distraction — Lilly has escalated a whistleblower-law fight to the U.S. Supreme Court; while not a direct revenue risk today, legal headlines can add regulatory/PR noise. Indy Pharma Giant Eli Lilly Takes Whistleblower Law Fight To Supreme Court

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.